The sensitivities to the different imaging modalities depend on the presence of PGL versus PCC, HN PGLs, sporadic metastatic, or non-metastatic disease, cluster 1 Krebs cycle-related SDHx mutations and VHL/EPAS1 pseudohypoxia-related mutations or cluster 2 kinase signaling-associated mutations (Table 2) [64]. This evidence concerns the gene EPAS1 and metastatic neoplasm.